XML 37 R26.htm IDEA: XBRL DOCUMENT
v3.21.4

Revenue from Contracts with Customers (Tables) | 6 Months Ended
--- | ---
Nov. 30, 2021
Revenue from Contract with Customer [Abstract] |
Disaggregation of Revenue | The following table summarizes net sales by Global Business Unit ("GBU") and geography:
| Three Months Ended Nov 30, 2021 |  | Three Months Ended Nov 30, 2020
(in thousands) | United States |  | International |  | Total |  | United States |  | International |  | Total
Net sales |  |  |  |  |  |  |  |  |  |  |
Endovascular Therapies | $ | 36,253 |  |  | $ | 3,407 |  |  | $ | 39,660 |  |  | $ | 30,689 |  |  | $ | 3,211 |  |  | $ | 33,900 |
Vascular Access | 20,705 |  |  | 4,365 |  |  | 25,070 |  |  | 20,161 |  |  | 3,769 |  |  | 23,930 |
Oncology | 8,392 |  |  | 5,158 |  |  | 13,550 |  |  | 9,834 |  |  | 5,106 |  |  | 14,940 |
Total | $ | 65,350 |  |  | $ | 12,930 |  |  | $ | 78,280 |  |  | $ | 60,684 |  |  | $ | 12,086 |  |  | $ | 72,770 |
| Six Months Ended Nov 30, 2021 |  | Six Months Ended Nov 30, 2020
(in thousands) | United States |  | International |  | Total |  | United States |  | International |  | Total
Net sales |  |  |  |  |  |  |  |  |  |  |
Endovascular Therapies | $ | 71,006 |  |  | $ | 6,712 |  |  | $ | 77,718 |  |  | $ | 57,669 |  |  | $ | 6,088 |  |  | $ | 63,757 |
Vascular Access | 41,180 |  |  | 8,846 |  |  | 50,026 |  |  | 39,383 |  |  | 12,652 |  |  | 52,035 |
Oncology | 17,628 |  |  | 9,879 |  |  | 27,507 |  |  | 17,740 |  |  | 9,454 |  |  | 27,194 |
Total | $ | 129,814 |  |  | $ | 25,437 |  |  | $ | 155,251 |  |  | $ | 114,792 |  |  | $ | 28,194 |  |  | $ | 142,986 |
As the Company has previously announced, the Company is focused on its ongoing transformation from a company with a broad portfolio of largely undifferentiated products to a more focused medical technology company that delivers unique and innovative health care solutions. The Company believes that this transformation will enable the Company to shift the portfolio from the mature, lower-growth markets where we have competed in the past by investing in technology and products that provide access to larger and faster growing markets. As such, we believe the growth in the near to mid-term will be driven by our high technology products including Auryon, Thrombectomy (which includes AngioVac, AlphaVac and thrombolytics) and NanoKnife. We will refer to these high technology products as our Med Tech business and we will refer to the remainder of the portfolio as our Med Device business. The following table summarizes net sales by Med Tech and Med Device:
| Three Months Ended |  | Six Months Ended
(in thousands) | Nov 30, 2021 |  | Nov 30, 2020 |  | Nov 30, 2021 |  | Nov 30, 2020
Net Sales |  |  |  |  |  |  |
Med Tech | $ | 18,886 |  |  | $ | 13,849 |  |  | $ | 36,504 |  |  | $ | 24,335 |
Med Device | 59,394 |  |  | 58,921 |  |  | 118,747 |  |  | 118,651 |
Total | $ | 78,280 |  |  | $ | 72,770 |  |  | $ | 155,251 |  |  | $ | 142,986 |
Contract Balances with Customers | The following table presents changes in the Company’s receivables, contract assets and contract liabilities with customers:
(in thousands) | Nov 30, 2021 |  | May 31, 2021
Receivables | $ | 38,205 |  |  | $ | 35,405 |
Contract assets | $ | — |  |  | $ | — |
Contract liabilities | $ | 690 |  |  | $ | 426 |

X
- Definition Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045 + Details
Name: | us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration